Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T14:46:29.989Z.
Calculation as of: 2026-10-06T14:46:29.989Z.
Quote observation: 2026-10-06T14:45:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5d6bd3278d76725a85d4cb05495e45b99d0fd89b23371e3701c8289362793e8f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$759.58M
EV/FCF Ratio
15.70x
TTM Avg
16.95x
3Y Avg
18.56x
5Y Avg
27.11x
Market Cap
$768.46M
EV/FCF Ratio
N/A
TTM Avg
3.79x
3Y Avg
3.79x
5Y Avg
6.31x
Market Cap
$723.04M
EV/FCF Ratio
N/A
TTM Avg
1185.88x
3Y Avg
1179.74x
5Y Avg
1179.74x
Market Cap
$722.55M
EV/FCF Ratio
N/A
TTM Avg
26.28x
3Y Avg
227.60x
5Y Avg
393.69x
Market Cap
$721.69M
EV/FCF Ratio
N/A
TTM Avg
3.46x
3Y Avg
3.45x
5Y Avg
3.45x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $749.48M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $750.01M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $743.33M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $759.58M | 15.70x | 16.95x | 18.56x | 27.11x |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $768.46M | N/A | 3.79x | 3.79x | 6.31x |
| Geron Corporation (GERN)vs › | $773.03M | N/A | 58.32x | 58.32x | 58.32x |
| Avalo Therapeutics, Inc. (AVTX)vs › | $723.04M | N/A | 1185.88x | 1179.74x | 1179.74x |
| Cytek Biosciences, Inc. (CTKB)vs › | $722.55M | N/A | 26.28x | 227.60x | 393.69x |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.69M | N/A | 3.46x | 3.45x | 3.45x |
| Gyre Therapeutics, Inc. (GYRE)vs › | $783.77M | N/A | 402.12x | 246.51x | 209.59x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
